80026098EM: Biomarkers and Beyond: Redefining Systemic Therapy for NSCLC (EM)

Please go to course content

Release Date: 12/19/11
Expiration Date: 12/19/12

This educational activity is designed to meet the needs of the oncologist, pathologist, radiologist, and other healthcare professionals involved or interested in the treatment of patients with lung cancer.

There are no prerequisites to participate in this program.

Lung cancer is the leading cause of worldwide cancer mortality and is responsible for more deaths annually in the U.S. than the combination of breast, colorectal, and prostate cancer. About 87% of lung cancer cases in the U.S. are classified as non-small cell lung cancer (NSCLC), and most cases are diagnosed at an advanced stage resulting in poor overall survival for most patients. Advanced NSCLC is incurable, and thus the goal of therapy is not only to improve survival times, but also to assure the best quality of life possible. Recently, treatment for advanced NSCLC has expanded beyond using chemotherapy as the cornerstone of treatment to include a new generation of targeted therapies that disrupt the cellular pathways involved in tumor growth, progression, and cell death.

The use of molecularly targeted therapies represents a significant advancement in the NSCLC treatment. Oncologists can improve the prognosis of patients with advanced NSCLC by learning how to incorporate the latest evidence-based recommendations regarding molecularly targeted therapies and emerging clinical evidence into individualized treatment plans that target the underlying heterogeneous molecular pathways of tumor progression.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

Presenter:
Jyoti D. Patel, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Feinberg School of Medicine
Northwestern University
Chicago, IL

Program Chair:
David S. Ettinger, MD, FACP, FCCP (Course Chair)
Alex Grass Professor of Oncology
The Johns Hopkins University School of Medicine
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Policy On Speaker And Provider Disclosure

It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.